Previous studies of COVID-19 showed that albumin was an important prognostic factor, and that a higher baseline level was associated with a decreased risk of adverse events, such as venous thromboembolism, acute respiratory distress syndrome, ICU admission, and mortality during hospitalization (Kheir et al., 2021). This evidence concerns the gene ALB and COVID-19.